Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBIT (2017 - 2025)

Historic EBIT for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to -$142.6 million.

  • Crinetics Pharmaceuticals' EBIT fell 6240.42% to -$142.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$477.8 million, marking a year-over-year decrease of 5576.9%. This contributed to the annual value of -$338.9 million for FY2024, which is 5222.0% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' EBIT is -$142.6 million, which was down 6240.42% from -$129.1 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' EBIT registered a high of -$22.9 million during Q1 2021, and its lowest value of -$142.6 million during Q3 2025.
  • In the last 5 years, Crinetics Pharmaceuticals' EBIT had a median value of -$56.0 million in 2023 and averaged -$66.3 million.
  • As far as peak fluctuations go, Crinetics Pharmaceuticals' EBIT tumbled by 2311.53% in 2023, and later crashed by 6240.42% in 2025.
  • Crinetics Pharmaceuticals' EBIT (Quarter) stood at -$30.9 million in 2021, then plummeted by 53.96% to -$47.6 million in 2022, then tumbled by 31.76% to -$62.7 million in 2023, then plummeted by 51.21% to -$94.7 million in 2024, then tumbled by 50.49% to -$142.6 million in 2025.
  • Its EBIT stands at -$142.6 million for Q3 2025, versus -$129.1 million for Q2 2025 and -$111.4 million for Q1 2025.